{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"52.83","upperLimit":"91.78","value":"76.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"Overall response rate will be estimated by the total number of patients who achieve a CR, very good partial response (VGPR), or partial response (PR) divided by the total number of evaluable patients. All evaluable patients will be used for this analysis. Exact binomial 95% confidence intervals for the true overall response rate will be calculated. Response is categorized by Response Assessment Criteria as specified in Appendix III of the protocol.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive ixazomib citrate PO on days 1, 8, and 15 and ibrutinib PO daily on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.\n\n\\>\n\n\\> Ibrutinib: Given PO\n\n\\>\n\n\\> Ixazomib Citrate: Given PO\n\n\\>\n\n\\> Laboratory Biomarker Analysis: Correlative studies\n\n\\>\n\n\\> Pharmacodynamic Study: Correlative studies\n\n\\>\n\n\\> Pharmacokinetic Study: Correlative studies","id":"OG000","title":"Treatment (Ixazomib Citrate, Ibrutinib)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Overall Response Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}